Inspection Record

Stanley Specialty Pharmacy Compounding and Wellness Center — FDA 483 Findings

US FDAInspected 2016-08-08Published 2024-01-17 4 findingsContamination controlAseptic processing and sterility assurance

Inspectors Bonita S ChesterThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Contamination control

Protective apparel is not worn as necessary to protect drug products from contamination.

2Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the areas to produce aseptic conditions.

3Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

4Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Stanley Specialty Pharmacy Compounding and Wellness Center company profile — full history US FDA documents, 2024 Go to Findings search